Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Neglected aspects of drug discovery--microbiological aspects.

Golenser J, Hunt N.

Curr Clin Pharmacol. 2013 Feb 1;8(1):73-80. Review.

PMID:
22946866
2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Novel trends in high-throughput screening.

Mayr LM, Bojanic D.

Curr Opin Pharmacol. 2009 Oct;9(5):580-8. doi: 10.1016/j.coph.2009.08.004. Review.

PMID:
19775937
4.

Drosophila melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds.

Chamilos G, Samonis G, Kontoyiannis DP.

Curr Pharm Des. 2011;17(13):1246-53. Review.

PMID:
21470115
5.

Cancer Drug Development: New Targets for Cancer Treatment.

Curt GA.

Oncologist. 1996;1(3):II-III.

PMID:
10387987
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
8.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
9.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Review.

PMID:
22584864
10.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
11.

[Prospects for development of new antituberculous drugs].

Tomioka H.

Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID:
12235850
12.
13.

Virulence on the fly: Drosophila melanogaster as a model genetic organism to decipher host-pathogen interactions.

Limmer S, Quintin J, Hetru C, Ferrandon D.

Curr Drug Targets. 2011 Jun;12(7):978-99. Review.

PMID:
21366519
14.

Pharmacological synergy: the next frontier on therapeutic advancement for migraine.

Blumenfeld A, Gennings C, Cady R.

Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Review.

PMID:
22221151
15.

Application of NMR and molecular docking in structure-based drug discovery.

Stark JL, Powers R.

Top Curr Chem. 2012;326:1-34. doi: 10.1007/128_2011_213. Review.

PMID:
21915777
16.

Bioprospecting microbial natural product libraries from the marine environment for drug discovery.

Liu X, Ashforth E, Ren B, Song F, Dai H, Liu M, Wang J, Xie Q, Zhang L.

J Antibiot (Tokyo). 2010 Aug;63(8):415-22. doi: 10.1038/ja.2010.56. Review.

PMID:
20606699
17.

Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.

Zuegg J, Cooper MA.

Curr Top Med Chem. 2012;12(14):1500-13. Review.

PMID:
22827520
18.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

19.

Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics.

Obrecht D, Robinson JA, Bernardini F, Bisang C, DeMarco SJ, Moehle K, Gombert FO.

Curr Med Chem. 2009;16(1):42-65. Review.

PMID:
19149562
20.

Enhancements of screening collections to address areas of unmet medical need: an industry perspective.

Drewry DH, Macarron R.

Curr Opin Chem Biol. 2010 Jun;14(3):289-98. doi: 10.1016/j.cbpa.2010.03.024. Review.

PMID:
20413343

Supplemental Content

Support Center